BioAtla, Inc. (BCAB)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
5.69 USD
+1.10
(23.965%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:22 p.m. EDT
BioAtla (BCAB) is facing a high-risk existence crisis. Despite a reverse split and media coverage of a 'Buy' rating, the fundamentals are dire: negative book value, negative operating cash flow, and a massive discrepancy between its $1.00 bid rule and its current price/capitalization. The data suggests a classic 'value trap' where basic technicals and deep put flow indicate capitulation. Investors should treat any price recovery with extreme skepticism until balance sheet solvency is proven. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.413510 |
| MSTL | 0.556481 |
| AutoETS | 0.597524 |
| AutoARIMA | 0.597524 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 56% |
| H-stat | 2.30 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.768 |
| Excess Kurtosis | 0.52 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 1.7 |
| Market Cap | 9,427,915 |
| Forward P/E | -4.26 |
| Beta | 1.21 |
| Website | https://www.bioatla.com |
As of April 18, 2026, 11:22 p.m. EDT: Options market shows heavy bearish positioning concentrated in out-of-the-money puts (especially 2026-07-17) with large volume (130 contracts) and sizeable open interest (238) at strikes of $0.50, $1.50, and $2.50. This indicates a significant speculative flight-to-safety, with traders anticipating a potential gap down or continued downtrend. In contrast, call activity is heavily skewed to deep out-of-the-money strikes ($0.50), suggesting minimal genuine upside conviction compared to the protective hedging or short-building seen in the puts. The ATM IV for near-term expirations is also volatile (51.25% for July puts), signaling high uncertainty and fear regarding downside risk.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.67109823 |
| Address1 | 11,085 Torreyana Road |
| All Time High | 3,831.5 |
| All Time Low | 3.92 |
| Ask | 5.36 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Daily Volume10 Day | 68,830 |
| Average Daily Volume3 Month | 50,307 |
| Average Volume | 50,307 |
| Average Volume10Days | 68,830 |
| Beta | 1.207 |
| Bid | 4.83 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | -28.511 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.69 |
| Current Ratio | 0.366 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.69 |
| Day Low | 4.58 |
| Display Name | BioAtla |
| Earnings Call Timestamp End | 1,763,069,400 |
| Earnings Call Timestamp Start | 1,763,069,400 |
| Earnings Timestamp | 1,774,987,200 |
| Earnings Timestamp End | 1,778,616,000 |
| Earnings Timestamp Start | 1,778,616,000 |
| Ebitda | -58,332,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.146 |
| Enterprise To Revenue | 4.255 |
| Enterprise Value | 8,509,909 |
| Eps Forward | -1.33667 |
| Eps Trailing Twelve Months | -50.5 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 558 0709 |
| Fifty Day Average | 7.7971 |
| Fifty Day Average Change | -2.1071 |
| Fifty Day Average Change Percent | -0.2702415 |
| Fifty Two Week Change Percent | -67.109825 |
| Fifty Two Week High | 71.5 |
| Fifty Two Week High Change | -65.81 |
| Fifty Two Week High Change Percent | -0.9204196 |
| Fifty Two Week Low | 3.92 |
| Fifty Two Week Low Change | 1.77 |
| Fifty Two Week Low Change Percent | 0.4515306 |
| Fifty Two Week Range | 3.92 - 71.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,608,129,000,000 |
| Float Shares | 1,383,053 |
| Forward Eps | -1.33667 |
| Forward P E | -4.2568474 |
| Free Cashflow | -22,801,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -41,073,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.05626 |
| Held Percent Institutions | 0.2045 |
| Implied Shares Outstanding | 1,656,927 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-12-16 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,775,433,600 |
| Last Split Factor | 1:50 |
| Long Business Summary | BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California. |
| Long Name | BioAtla, Inc. |
| Market | us_market |
| Market Cap | 9,427,915 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_105291463 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -59,607,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 9,427,908 |
| Open | 4.59 |
| Operating Cashflow | -48,204,000 |
| Operating Margins | -4.6275 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 858 558 0708 |
| Pre Market Change | 0.0 |
| Pre Market Change Percent | 0.0 |
| Pre Market Price | 5.69 |
| Pre Market Time | 1,776,770,099 |
| Previous Close | 4.59 |
| Price Hint | 2 |
| Price To Book | -0.1995721 |
| Price To Sales Trailing12 Months | 4.7139573 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.325 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 1.1 |
| Regular Market Change Percent | 23.9651 |
| Regular Market Day High | 5.69 |
| Regular Market Day Low | 4.58 |
| Regular Market Day Range | 4.58 - 5.69 |
| Regular Market Open | 4.59 |
| Regular Market Previous Close | 4.59 |
| Regular Market Price | 5.69 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 131,529 |
| Return On Assets | -1.10764 |
| Revenue Per Share | 1.7 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 1,656,926 |
| Shares Percent Shares Out | 0.0286 |
| Shares Short | 47,314 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 40,915 |
| Short Name | BioAtla, Inc. |
| Short Percent Of Float | 0.0301 |
| Short Ratio | 1.71 |
| Source Interval | 15 |
| State | CA |
| Symbol | BCAB |
| Total Cash | 7,118,000 |
| Total Cash Per Share | 4.296 |
| Total Debt | 6,200,000 |
| Total Revenue | 2,000,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -50.5 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.632275 |
| Two Hundred Day Average Change | -17.942274 |
| Two Hundred Day Average Change Percent | -0.7592276 |
| Type Disp | Equity |
| Volume | 131,529 |
| Website | https://www.bioatla.com |
| Zip | 92,121 |